Neostigmine Information & Neostigmine Links at HealthHaven.com

Neostigmine
Systematic (IUPAC) name
	3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylbenzenaminium
Identifiers
CAS number	59-99-4
ATC code	N07AA01 S01EB06 QA03AB93
PubChem	5824
Chemical data
Formula	C12H19N2O2
Mol. mass	223.294 g/mol
Pharmacokinetic data
Bioavailability	Unclear, probably less than 5%
Metabolism	Slow hydrolysis by acetylcholinesterase and also by plasma esterases
Half life	50–90 minutes
Excretion	Unchanged drug (up to 70%) and alcoholic metabolite (30%) are excreted in the urine
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?
	(what is this?) (verify);

Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor.

Neostigmine is available under several trade names such as Prostigmin and Vagostigmin.

[edit] Synthesis

Neostigmine was first synthesized by Aeschlimann and Reinert in 1931.

Neostigmine is made by first reacting 3-dimethylaminophenol with N-dimethylcarbamoyl chloride, which forms a dimethylcarbamate. Next, that product is alkylated using dimethylsulfate, which forms neostigmine.^[1]

[edit] Pharmacology

By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors. Unlike physostigmine, neostigmine has a quarternary nitrogen; hence, it is more polar and does not enter the CNS. its effect on skeletal muscle is greater than that of physostigmine, and it can stimulate contractility before it paralyzes. Neostigmine has short duration of action, usually thirty minutes to two hours.^[2] Neostigmine binds to the anionic site of cholinesterase. The drug blocks the active site of acetylcholinesterase so the enzyme can no longer break down the acetylcholine molecules before they reach the postsynaptic membrane receptors. This allows for the threshold to be reached so a new impulse can be triggered in the next neuron. In myasthenia gravis there are too few acetylcholine receptors so with the acetylcholinesterase blocked, acetylcholine can bind to the few receptors and trigger a muscular contraction.

[edit] Clinical uses

It is used to improve muscle tone in people with myasthenia gravis and routinely, in anesthesia at the end of an operation, to reverse the effects of non-depolarizing muscle relaxants such as rocuronium and vecuronium.

It can also be used for urinary retention resulting from general anaesthesia and to treat curariform drug toxicity.

Another indication for use is the Ogilvie syndrome which is a pseudoobstruction of the colon in critically ill patients.

Historically, it has been used as a test for early pregnancy. In a non-pregnant female whose menstrual period is delayed, administration of neostigmine can provoke menstrual bleeding. Modern tests which rely on detecting hCG in urine have rendered this application obsolete.

Though one of only two treatments available for myasthenia gravis this drug is no longer available to anyone using the Medicare Part D program.

[edit] Side Effects

Neostigmine can induce generic occular side effects including: headache, brow pain, blurred vision, phacodinesis,pericorneal injection, congestive iritis, various allergic reactions, and rarely, retinal detachment.^[3]

Neostigmine will cause slowing of the heart rate (bradycardia), for this reason it is usually given along with a parasympatholytic drug such as atropine or glycopyrrolate.

Gastrointestial symptoms occur earliest after ingestion and include anorexia, nausea and vomiting, abdominal cramps and diarrhea.^[4]

[edit] Spectral Data

Neostigmine shows notable UV/VIS absorption at 261nm, 267nm, and 225nm.^[5]

Neostigmine's ¹H NMR Spectroscopy reveals shifts at: 7.8, 7.7, 7.4, 7.4, 3.8, and 3.1 parts per million. The higher shifts are due to the aromatic hydrogens. The lower shifts at 3.8ppm and 3.1ppm are due to the electronic withdrawing nature of the tertiary and quaterary nitrogen, respectively.^[6]

[edit] See also

Miotine

[edit] Notes

^ Gilman, A.G..; Goodman L.S.; Gilman A. Goodman and Guildman's The Pharmacological Basis of Therapeutics; 6th ed. Macmillan Publishing Co., Inc., 1980; pp 103
^ Howland, R. D., Mycek, M. J., Harvey, R. A., Champe, P. C., & Mycek, M. J. Pharmacology 3rd edition, Lippincott's Illustrated Reviews, 2008, pg. 51.
^ [Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980.,p.114]
^ [Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p.109]
^ Porst, Hella; Kny, L. Pharmazie, 1985 , vol. 40, # 5 p. 325 - 328
^ Ferdous, Abu J.; Waigh, Roger D. Journal of Pharmacy and Pharmacology, 1993 , vol. 45, # 6 p. 559 - 562

[edit] References

Brenner, G. M. (2000). Pharmacology. Philadelphia, Penn.: W.B. Saunders Company. ISBN 0-7216-7757-6.
Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4.

[0] Gilman, A.G..; Goodman L.S.; Gilman A. Goodman and Guildman's The Pharmacological Basis of Therapeutics; 6th ed. Macmillan Publishing Co., Inc., 1980; pp 103

[1] Howland, R. D., Mycek, M. J., Harvey, R. A., Champe, P. C., & Mycek, M. J. Pharmacology 3rd edition, Lippincott's Illustrated Reviews, 2008, pg. 51.

[2] [Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980.,p.114]

[3] [Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p.109]

[4] Porst, Hella; Kny, L. Pharmazie, 1985 , vol. 40, # 5 p. 325 - 328

[5] Ferdous, Abu J.; Waigh, Roger D. Journal of Pharmacy and Pharmacology, 1993 , vol. 45, # 6 p. 559 - 562

[1]

[2]

[3]

[4]

[5]

[6]

Contents